Head-To-Head Survey: Innate Pharma (IPHA) vs. The Competition
Innate Pharma (NASDAQ: IPHA) is one of 138 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Innate Pharma to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.
This is a summary of recent ratings for Innate Pharma and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innate Pharma Competitors||1296||3840||7757||354||2.54|
Earnings & Valuation
This table compares Innate Pharma and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Innate Pharma||$96.12 million||-$23.25 million||-15.29|
|Innate Pharma Competitors||$759.44 million||$139.43 million||3.30|
Innate Pharma’s competitors have higher revenue and earnings than Innate Pharma. Innate Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
48.8% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 17.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Innate Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innate Pharma Competitors||-4,591.72%||-149.77%||-36.94%|
Innate Pharma competitors beat Innate Pharma on 7 of the 12 factors compared.
About Innate Pharma
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.